Identification and Interaction Analysis of Key Genes and MicroRNAs in Systemic Sclerosis by Bioinformatics Approaches

Abstract

Systemic sclerosis (SSc) is a highly heterogeneous autoimmune disease with a high mortality rate. However, the cellular and molecular mechanisms of SSc remain unclear. Here, we identified the key hub genes and microRNAs (miRNAs) that modulate the occurrence and development of SSc. We downloaded the microarray dataset GSE95065 from the Gene Expression Omnibus (GEO) database and then analyzed the data by using GEO2R. The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used for functional pathway enrichment analyses of differentially expressed genes (DEGs), and Cytoscape software was used to generate the protein-protein interaction (PPI) network. In addition, OmicsNet was used to predict the miRNAs for the hub genes of SSc. As a result, 783 DEGs were identified, of which 770 genes (142 up-regulated genes and 628 down-regulated genes) were matched to the genes in SSc skin samples. Gene Ontology (GO) analyses by DAVID indicated that the up-regulated genes were mainly involved in immune response, and the down-regulated genes were greatly enriched in glycinergic synaptic transmission. In the PPI network, 22 nodes were selected as key genes, including several members of the chemokine family. Furthermore, after uploading these key genes to the OmicsNet tool, we found that hsa-miR-26b-5p might target CXCL9 and CXCL13. Moreover, we demonstrated that the hsa-miR-26b-5p inhibitor might inhibit fibrosis in TGF-β-activated fibroblasts, which would be a promising target for SSc therapy.

References

[1] BarnesJ, MayesMD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol, 2012, 24(2): 165-170

[2] DentonCP. Advances in pathogenesis and treatment of systemic sclerosis. Clin Med (Lond), 2016, 16(1): 55-60

[3] DentonCP. Systemic sclerosis: from pathogenesis to targeted therapy. Clin Exp Rheumatol, 2015, 33(4Suppl92): S3-S7

[4] ZuoX, ZhangL, LuoH, et al.. Systematic approach to understanding the pathogenesis of systemic sclerosis. Clin Genet, 2017, 92(4): 365-371

[5] SingT, JinninM, YamaneK, et al.. microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma. Rheumatology (Oxford), 2012, 51(9): 1550-1556

[6] ZhuH, LuoH, LiY, et al.. MicroRNA-21 in scleroderma fibrosis and its function in TGF-beta-regulated fibrosis-related genes expression. J Clin Immunol, 2013, 33(6): 1100-1109

[7] MiaoCG, XiongYY, YuH, et al.. Critical roles of microRNAs in the pathogenesis of systemic sclerosis: New advances, challenges and potential directions. Int Immunopharmacol, 2015, 28(1): 626-633

[8] CloughE, BarrettT. The Gene Expression Omnibus Database. Methods Mol Biol, 2016, 1418: 93-110

[9] XiaJ, GillEE, HancockRE. NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data. Nat Protoc, 2015, 10(6): 823-844

[10] Gene OntologyC. The Gene Ontology (GO) project in 2006. Nucleic Acids Res, 2006, 34: D322-326

[11] LewisSE. The Vision and Challenges of the Gene Ontology. Methods Mol Biol, 2017, 1446: 291-302

[12] KanehisaM, SatoY, KawashimaM, et al.. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res, 2016, 44(D1): D457-462

[13] HuangDW, ShermanBT, TanQ, et al.. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res, 2007, 35: W169-175

[14] SzklarczykD, FranceschiniA, WyderS, et al.. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res, 2015, 43: D447-452

[15] SuG, MorrisJH, DemchakB, et al.. Biological network exploration with Cytoscape 3. Curr Protoc Bioinformatics, 2014, 47: 8.13.1-24

[16] ZhouG, XiaJ. OmicsNet: a web-based tool for creation and visual analysis of biological networks in 3D space. Nucleic Acids Res, 2018, 46(W1): W514-W522

[17] EliaG, GuglielmiG. CXCL9 chemokine in ulcerative colitis. Clin Ter, 2018, 169(5): e235-e241

[18] DingQ, LuP, XiaY, et al.. CXCL9: evidence and contradictions for its role in tumor progression. Cancer Med, 2016, 5(11): 3246-3259

[19] DuarteGV, BoeiraV, CorreiaT, et al.. Osteopontin, CCL5 and CXCL9 are independently associated with psoriasis, regardless of the presence of obesity. Cytokine, 2015, 74(2): 287-292

[20] SuR, NguyenML, AgarwalMR, et al.. Interferon-inducible chemokines reflect severity and progression in sarcoidosis. Respir Res, 2013, 14: 121

[21] WenzelJ, TutingT. Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. Exp Dermatol, 2007, 16(5): 454-463

[22] O’BrienJC, RainwaterYB, MalviyaN, et al.. Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea. J Invest Dermatol, 2017, 137(8): 1663-1670

[23] RabquerBJ, TsouPS, HouY, et al.. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther, 2011, 13(1): R18

[24] HasegawaM, FujimotoM, MatsushitaT, et al.. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol, 2011, 30(2): 231-237

[25] HasegawaM, AsanoY, EndoH, et al.. Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. Mod Rheumatol, 2013, 23(6): 1076-1084

[26] KuoPT, ZengZ, SalimN, et al.. The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer. Front Med (Lausanne), 2018, 5: 271

[27] FazilleauN, MarkL, McHeyzer-WilliamsLJ, et al.. Follicular helper T cells: lineage and location. Immunity, 2009, 30(3): 324-335

[28] LimHW, HillsamerP, KimCH. Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. J Clin Invest, 2004, 114(11): 1640-1649

[29] ShiK, HayashidaK, KanekoM, et al.. Lymphoid Chemokine B Cell-Attracting Chemokine-1 (CXCL13) Is Expressed in Germinal Center of Ectopic Lymphoid Follicles within the Synovium of Chronic Arthritis Patients. J Immunol, 2001, 166(1): 650-655

[30] IshikawaS, SatoT, AbeM, et al.. Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by C11b+CD11c+ dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. J Exp Med, 2001, 193(12): 1393-1402

[31] KramerJM, KlimatchevaE, RothsteinTL. CXCL13 is elevated in Sjogren’s syndrome in mice and humans and is implicated in disease pathogenesis. J Leukoc Biol, 2013, 94(5): 1079-1089

[32] WutteN, KovacsG, BergholdA, et al.. CXCL13 and B-cell activating factor as putative biomarkers in systemic sclerosis. Br J Dermatol, 2013, 169(3): 723-725

[33] TaniguchiT, MiyagawaT, ToyamaS, et al.. CXCL13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis. Exp Dermatol, 2018, 27(9): 1030-1037

[34] AmmiranteM, ShalapourS, KangY, et al.. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci USA, 2014, 111(41): 14776-14781

[35] WeiY, LinC, LiH, et al.. CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. Cancer Immunol Immunother, 2018, 67(2): 261-269

[36] ZhuZ, ZhangX, GuoH, et al.. CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K/AKT pathway. Mol Cell Biochem, 2015, 400(1-2): 287-295

[37] CaiY, YuX, HuS, et al.. A brief review on the mechanisms of miRNA regulation. Genomics, Proteomics Bioinformatics, 2009, 7(4): 147-154

[38] MiaoCG, XiongYY, YuH, et al.. Critical roles of microRNAs in the pathogenesis of systemic sclerosis: New advances, challenges and potential directions. Int Immunopharmacol, 2015, 28(1): 626-633

[39] JiaCM, TianYY, QuanLN, et al.. miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1. Pathol Res Pract, 2018, 214(9): 1388-1394

[40] FanF, LuJ, YuW, et al.. MicroRNA-26b-5p regulates cell proliferation, invasion and metastasis in human intrahepatic cholangiocarcinoma by targeting S100A7. Oncol Lett, 2018, 15(1): 386-392

[41] TangCM, ZhangM, HuangL, et al.. CircRNA_000203 enhances the expression of fibrosis-associated genes by derepressing targets of miR-26b-5p, Col1a2 and CTGF, in cardiac fibroblasts. Sci Rep, 2017, 7: 40342

[42] ChouriE, ServaasNH, BekkerCPJ, et al.. Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis. J Autoimmun, 2018, 89: 162-170

[43] RichmondA. Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol, 2002, 2(9): 664-674